Online inquiry

IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2976MR)

This product GTTS-WQ2976MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2976MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1465MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ5518MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ13077MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ11408MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ14518MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ7089MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ1838MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ15599MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW